Mark E. Bunnage
At a glance: Mark E. Bunnage is Evp, Chief Scientific Officer at Vertex Pharmaceuticals (VRTX). Their latest SEC Form 4, filed May 19, 2026, reported a sale of $15K. On file: 0 purchase lines ($0) and 5 sale lines ($3.0M).
Disclosed holdings: about $3.8M of VRTX stock: 7,284 shares reported on their latest Form 4 (filed May 19, 2026), valued at the Nov 19, 2026 close of $521.30. This counts only VRTX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Evp, Chief Scientific Officer at Vertex Pharmaceuticals Inc / Ma (VRTX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Mark E. Bunnage's InsiderPrint
5 trades from SEC Form 4 filings, 2026 to 2026, drawn as one fingerprint.
Reading this print: Almost only sells, trading about 5 times a year, typically $560K a trade; most sales are on a pre-planned 10b5-1 schedule.
- Bump outward: a purchase (0)
- Dent inward: a sale (5)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Insiders with a similar print
- Ingrid DelaetChief Regulatory Officer · NBIX · 100% match
- Shibu NinanChief Accounting Officer · OKTA · 100% match
- Christopher Scott EdmondsPresident · ICE · 100% match
- Edward Morrow Atkinson IIIEvp, Chief Technical Ops. Off. · VRTX · 100% match
- Eric A. Hughes"See ""Remarks""" · TEVA · 100% match
Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| May 19SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 337,284 held (−0%) | $453.45 | $15K | +15.0% |
| Feb 26SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 6207,284 held (−8%) | $486.35 | $302K | +7.2% |
| Feb 19SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,4379,668 held (−20%) | $489.46 | $1.2M | +6.5% |
| Feb 19SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 1,1828,486 held (−12%) | $473.68 | $560K | +10.1% |
| Feb 12SEC | VRTXVertex Pharmaceuticals Inc / Ma | Sell Plan | 2,02112,914 held (−14%) | $460.43 | $931K | +13.2% |
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $15K of VRTX at $453.45 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $302K of VRTX at $486.35 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $1.2M of VRTX at $489.46 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $560K of VRTX at $473.68 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp, Chief Scientific Officer Mark E. Bunnage sold $931K of VRTX at $460.43 — pre-scheduled 10b5-1 plan sale.
Follow Mark E. Bunnage
Get one email when Mark E. Bunnage files a new purchase or sale. Free.
At most one email a day about Mark E. Bunnage, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.